Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
1 drug for “Non-muscle Invasive Bladder Cancer With Carcinoma in Situ”
Phase 3 1
- TARA-002Protara Therapeutics, Inc.Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.